

### REMARKS/ARGUMENTS

Reconsideration of this application is requested. Claims 1, 4, 5, 7-9 and 13-16 are pending in the application of which claims 1, 4, 5 and 7-9 are directed to elected subject matter.

The remaining claims 13-16 have been withdrawn from consideration as directed to non-elected subject matter, however applicants request that these claims be rejoined as the claims directed to compounds *per se* are believed to be in allowable condition.

An Abstract of the Disclosure on a separate sheet of paper is provided with this response. The Abstract is based upon that used in the published PCT application.

A certified copy of the Italian priority document will be filed as soon as it is available.

The claims have been amended in order to more particularly point out and distinctly claim that which applicants regard as their invention, to direct them exclusively to elected subject matter and to place them in condition for allowance following the comments made in the Official Action.

Claim 1 has been amended to incorporate the subject matter of claim 2 and the  $n = 4-7$  of claim 4. Claim 3 has been deleted as outside the scope of the elected subject matter. Claim 5 has been amended to delete those compounds falling outside of amended claim 1.

The requirement for restriction of April 23, 2007 indicates for Group I, the elected Group, that the variable Z is as defined in claim 2 and Q, W, X and Y are as in claim 1. The Z variable of claim 1 has been amended to be that of claim 2 and in item 8 the examiner has indicated that  $n = 4-7$  would be allowable, in other words most of the subject matter of claim 4. Accordingly, the amendments proposed to claim 1 will place it in condition for allowance. Claims 2 and 3 have been deleted, claim 4 has been amended to account for that portion of the claim that is now part of claim 1. The non-relevant compounds of claim 5 have been deleted and claims 7-9 directed to pharmaceutical compositions remain as before.

As noted above, applicants request that claims 13-16 be rejoined and allowed together with the compound and composition claims.

Further consideration is requested. Should the examiner require further information, please contact the undersigned.

GIANNESSI et al.  
Appl. No. 10/537,269  
October 26, 2007

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



Arthur R. Crawford  
Reg. No. 25,327

ARC:eaw  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100